Our results show immunohistochemical expression of PTEN protein in all the cases used as internal controls, with this expression being moderate or intense from the immunohistochemical point of view in 96.3 % of the cases, which may reflect normal activity in this gene. No negative cases were observed, which may suggest some degree of PTEN inactivation in the non-tumor mucosa adjacent to the tumors. However, in the GBC there was a greater dispersion in the intensity of the positive staining, being weak in 54.5 % of the cases and moderate in 42.6 %, which may mean that the tumor tissues present a variable expression, possibly a reflection of differing degrees of PTEN activity or inactivation. This being a recessive gene, inactivation of an allele does not necessarily compromise its function entirely, as it can express itself partially [
24]. In most tumors the loss of PTEN is monoallelic (gliomas, breast, colon, lung), with biallelic being less frequent [
24‐
27], as inactivation due to methylation of promoter areas is one of the inactivation mechanisms that occurs more frequently than genomic alterations [
24,
28,
29]. Thus, the absence of PTEN expression in three cases of advanced GBC suggests is an infrequent phenomenon (4.1 % of all AC) and is also delayed since its inactivation could not be demonstrated through the loss of its expression in any of the 35 EC. There is little information about the inactivation of this gene in GBC measured using different molecular techniques. Some indicate inactivation frequencies ranging between 0 and 5 %, but this does not rule out that other PTEN inactivation mechanisms may be at work [
16]. On the other hand, the poor prognosis of the three patients with an absence of PTEN protein expression compared to patients at similar stages must be pointed out [
30]. In these patients, PTEN inactivation may have released the PI3k/AKT pathway, which through some of its effectors like mTOR is able to activate cell proliferation [
31]. Although PTEN inactivation is observed in around 4 % of the advanced cancers, it is worthy of note that the other inactivation mechanisms in this proliferative pathway and which promote tumor growth and development have recently been reported in significant percentages (
http://cancer.sanger.ac.uk, [
32‐
34]), which will open up important expectations for the use of selective blockers and inhibitors of this pathway as a targeted therapy in patients with advanced gallbladder cancers [
35‐
37]. Our recent work has shown activating mutations in exons 9 and 20 of the PI3k gene in 16.9 % of GBC, suggesting that this gene together with PTEN could be a therapeutic target in around 20 % of advanced gallbladder cancers (Roa et al., observations not published).